|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...2223242526272829303132...3940» |
- Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment open: PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia (clinicaltrials.gov) - Sep 19, 2013
P1, N=12, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Not yet recruiting --> Recruiting
- Clinical: Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation (clinicaltrials.gov) - Sep 18, 2013
P=N/A, N=546, Recruiting, Sponsor: Cambridge Health Alliance
- ||||| New P4 trial: A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia (clinicaltrials.gov) - Sep 18, 2013
P4, N=353, Recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
- Enrollment change: Specialized Treatment Early in Psychosis (STEP) (clinicaltrials.gov) - Sep 16, 2013
P=N/A, N=120, Completed, Sponsor: Yale University
Not yet recruiting --> Recruiting N=200 --> 120
- Trial completion: Specialized Treatment Early in Psychosis (STEP) (clinicaltrials.gov) - Sep 16, 2013
P=N/A, N=120, Completed, Sponsor: Yale University
N=200 --> 120 Recruiting --> Completed
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P1 trial: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Sep 12, 2013
P1, N=5, Recruiting, Sponsor: Monash University
- |||||| aripiprazole / Generic mfg.
Enrollment open: A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia (clinicaltrials.gov) - Sep 11, 2013
P2/3, N=99, Recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- clozapine / Generic mfg.
Enrollment change: Serum Clozapine and Cognition (clinicaltrials.gov) - Sep 10, 2013
P=N/A, N=10, Completed, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting N=100 --> 10
- | methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg.
New P4 trial, Combination therapy: A Study of Combination Therapy in Children With ADHD (clinicaltrials.gov) - Sep 10, 2013
P4, N=99, Recruiting, Sponsor: Douglas Sears
- ||| ulotaront (SEP-363856) / Otsuka, PsychoGenics
New P1 trial: A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (clinicaltrials.gov) - Sep 10, 2013
P1, N=60, Completed, Sponsor: Sunovion
- Enrollment open: Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia (clinicaltrials.gov) - Sep 10, 2013
P=N/A, N=30, Recruiting, Sponsor: Seoul National University Hospital
N=100 --> 10 Not yet recruiting --> Recruiting
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Sep 10, 2013
P1, N=5, Recruiting, Sponsor: Monash University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Epigenetic Regulation of BDNF in Schizophrenia (clinicaltrials.gov) - Sep 10, 2013
P=N/A, N=129, Completed, Sponsor: Chang Gung Memorial Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- clozapine / Generic mfg.
Trial completion: Serum Clozapine and Cognition (clinicaltrials.gov) - Sep 10, 2013
P=N/A, N=10, Completed, Sponsor: University of Aarhus
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change, IO biomarker: Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs (clinicaltrials.gov) - Sep 9, 2013
P=N/A, N=77, Completed, Sponsor: Chang Gung Memorial Hospital
Active, not recruiting --> Completed N=300 --> 77
- | methamphetamine / Generic mfg., haloperidol / Generic mfg., quetiapine / Generic mfg.
New P4 trial: Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis (clinicaltrials.gov) - Sep 9, 2013
P4, N=80, Completed, Sponsor: Chulalongkorn University
- ||| aripiprazole / Generic mfg.
New P3 trial: A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia (clinicaltrials.gov) - Sep 9, 2013
P3, N=30, Recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
- |||||||||| aripiprazole / Generic mfg.
New P2/3 trial: A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia (clinicaltrials.gov) - Sep 9, 2013
P2/3, N=99, Recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
- ||||| PF-02545920 / Pfizer
New P2 trial: An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia (clinicaltrials.gov) - Sep 9, 2013
P2, N=249, Recruiting, Sponsor: Pfizer
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P1 trial: A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia (clinicaltrials.gov) - Sep 9, 2013
P1, N=76, Completed, Sponsor: Janssen Pharmaceutical K.K.
- | aripiprazole / Generic mfg.
Enrollment open: A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia (clinicaltrials.gov) - Sep 9, 2013
P3, N=30, Recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
N=300 --> 77 Not yet recruiting --> Recruiting
- risperidone controlled-release implant (BB-0817) / Braeburn
Enrollment closed: Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant (clinicaltrials.gov) - Sep 9, 2013
P1, N=30, Active, not recruiting, Sponsor: Endo Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia (clinicaltrials.gov) - Sep 9, 2013
P1, N=76, Completed, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- Trial completion, IO biomarker: Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs (clinicaltrials.gov) - Sep 9, 2013
P=N/A, N=77, Completed, Sponsor: Chang Gung Memorial Hospital
Not yet recruiting --> Completed Recruiting --> Completed
- Enrollment open: Study of Repetitive Transcranial Magnetic Stimulation in the Treatment of Cognitive Impairment in Schizophrenia (clinicaltrials.gov) - Sep 8, 2013
P=N/A, N=70, Recruiting, Sponsor: Shanghai Mental Health Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment closed: A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Sep 3, 2013
P3, N=511, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Chantix (varenicline) / Pfizer
New P2 trial: VAR-PAS: Effects of Varenicline on Plasticity in Schizophrenia (clinicaltrials.gov) - Sep 2, 2013
P2, N=28, Recruiting, Sponsor: Centre for Addiction and Mental Health
- | paliperidone extended release / Generic mfg.
Enrollment change: A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug (clinicaltrials.gov) - Aug 28, 2013
P4, N=13, Completed, Sponsor: Janssen Korea, Ltd., Korea
Recruiting --> Active, not recruiting N=402 --> 13
- Enrollment change: Re-Entry MTC for Offenders With MICA Disorders (clinicaltrials.gov) - Aug 28, 2013
P=N/A, N=610, Completed, Sponsor: National Development and Research Institutes, Inc.
N=402 --> 13 N=332 --> 610
- | paliperidone extended release / Generic mfg.
Trial completion: A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug (clinicaltrials.gov) - Aug 28, 2013
P4, N=13, Completed, Sponsor: Janssen Korea, Ltd., Korea
N=332 --> 610 Recruiting --> Completed
- Trial completion: Re-Entry MTC for Offenders With MICA Disorders (clinicaltrials.gov) - Aug 28, 2013
P=N/A, N=610, Completed, Sponsor: National Development and Research Institutes, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- | iloperidone / Generic mfg.
New P4 trial: Assessing the Effects of Fanapt (clinicaltrials.gov) - Aug 26, 2013
P4, N=50, Recruiting, Sponsor: Northwestern University
- |||||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
Enrollment open: An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) (clinicaltrials.gov) - Aug 26, 2013
P3, N=300, Enrolling by invitation, Sponsor: Alkermes
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- | iloperidone / Generic mfg.
Enrollment open: Assessing the Effects of Fanapt (clinicaltrials.gov) - Aug 21, 2013
P4, N=50, Recruiting, Sponsor: Northwestern University
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- HEOR: MDWP: Influence of Multi-dimensional Wellness Program on Quality of Life (clinicaltrials.gov) - Aug 20, 2013
P=N/A, N=12166, Completed, Sponsor: MOA Health Science Foundation
- ||||| New P4 trial: HOSPIPalm: A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting (clinicaltrials.gov) - Aug 19, 2013
P4, N=450, Recruiting, Sponsor: Janssen-Cilag International NV
- clozapine / Generic mfg.
Enrollment open: Vitamin D for Schizophrenia (clinicaltrials.gov) - Aug 19, 2013
P=N/A, N=50, Recruiting, Sponsor: Geha Mental Health Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion, Adverse events: A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs) (clinicaltrials.gov) - Aug 12, 2013
P=N/A, N=240, Completed, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
Enrollment change: A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia (clinicaltrials.gov) - Aug 8, 2013
P1, N=88, Completed, Sponsor: Alkermes
Active, not recruiting --> Completed N=48 --> 88
- Enrollment change: NIC-PAS: Effects of Acute Nicotine Treatment on Neuroplasticity and Memory in Patients With Schizophrenia (clinicaltrials.gov) - Aug 8, 2013
P=N/A, N=20, Terminated, Sponsor: Centre for Addiction and Mental Health
N=48 --> 88 N=28 --> 20
- ||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
Trial completion: A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia (clinicaltrials.gov) - Aug 8, 2013
P1, N=88, Completed, Sponsor: Alkermes
N=28 --> 20 Recruiting --> Completed
- ||||||| lurasidone / Generic mfg.
Trial completion: PEARL Schizophrenia Maintenance (clinicaltrials.gov) - Aug 8, 2013
P3, N=285, Completed, Sponsor: Sunovion
Recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment closed: Smoking Cessation for Veterans With Severe and Persistent Mental Illness (clinicaltrials.gov) - Aug 6, 2013
P2/3, N=210, Active, not recruiting, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Chantix (varenicline) / Pfizer
Enrollment open: Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia (clinicaltrials.gov) - Aug 5, 2013
P4, N=50, Recruiting, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Trial completion: Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia (clinicaltrials.gov) - Aug 5, 2013
P3, N=86, Completed, Sponsor: Veterans Medical Research Foundation
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment closed: Cognitive Remediation in 22q11DS (clinicaltrials.gov) - Aug 4, 2013
P=N/A, N=36, Active, not recruiting, Sponsor: Duke University
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| bitopertin (DISC-1459) / Disc Medicine
Enrollment closed: A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309) (clinicaltrials.gov) - Aug 4, 2013
P3, N=624, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment change: Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations (clinicaltrials.gov) - Aug 1, 2013
P=N/A, N=50, Completed, Sponsor: Yale University
Recruiting --> Active, not recruiting N=40 --> 50
- |||||||||| lurasidone / Generic mfg.
New P3 trial: Pediatric Schizophrenia Efficacy and Safety Study (clinicaltrials.gov) - Jul 28, 2013
P3, N=249, Recruiting, Sponsor: Sunovion
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial initiation date: A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Jul 25, 2013
P3, N=1050, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
N=40 --> 50 Initiation date: Feb 2013 --> Jun 2013